Cite
HARVARD Citation
La Monica, S. et al. (2016). Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines CarryingEGFR‐Activating Mutation. Journal of thoracic oncology. 11 (7), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
La Monica, S. et al. (2016). Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines CarryingEGFR‐Activating Mutation. Journal of thoracic oncology. 11 (7), p. . [Online].